News for Providers
Top stories summarized by our editors
5/22/2018

Stick to the plans you make with your colleagues, and find time to interact with the new person in the office, writes entrepreneur Michael Volkmann. Show appreciation to co-workers who help you with a project by offering to help them with a task or treat them to a coffee.

Full Story:
Lifehacker
More Summaries:
Michael Volkmann
5/22/2018

The National Park Service said it intends to relax sport hunting and trapping regulations on federal lands in Alaska, aligning standards there with state rules that allow people to use dogs to hunt bears, using bait to lure bears, kill wolves and their pups in their dens, and use motorboats to hunt swimming caribou, among other changes. The public comment period is open for 60 days.

More Summaries:
National Park Service
5/22/2018

The Government Accountability Office released a report encouraging the CMS to continue its prior authorization demonstrations, which require providers and medical device suppliers to demonstrate compliance with payment and coverage rules before receiving payments for certain products and services. Estimates showed the CMS has saved up to $1.9 billion since the demonstrations started in 2012, but most of these programs have ended or will end soon.

5/22/2018

A study in Diabetes Research and Clinical Practice showed that patients with type 2 diabetes who achieved triple treatment targets for glycated hemoglobin less than 7%, blood pressure less than 140/90 mmHg and LDL cholesterol less than 100 mg/dl had a lower risk for mortality and macrovascular and microvascular complications than dual-goal, single-goal and no-goal achievers. Researchers used a cohort of 53,120 diabetes patients and found that management of LDL cholesterol levels was associated with a consistent reduction in possible complications.

Full Story:
Endocrinology Advisor
5/22/2018

Type 2 diabetes patients who used 0.5 mg and 1 mg of subcutaneous semaglutide experienced a 1.01% and a 1.38% reduction in A1C levels, respectively, compared with those on placebo, according to a study in Diabetes, Obesity and Metabolism. Greek researchers analyzed six placebo-controlled and seven active-controlled studies and found that semaglutide also had beneficial effects on body weight and systolic blood pressure.

More Summaries:
diabetes, semaglutide
5/22/2018

Researchers from the US and Canada used a cohort of 39 patients with prediabetes and obstructive sleep apnea and found that those who wore continuous positive airway pressure masks for two weeks had significantly lower resting heart rates than those on placebo. The findings in the American Journal of Respiratory and Critical Care Medicine revealed that "optimal treatment of sleep apnea reduces cardiovascular risk in those with prediabetes," said study author Dr. Esra Tasali.

Full Story:
Diabetes (UK)
5/22/2018

Researchers reviewed data from the Netherlands Epidemiology of Obesity study for thousands of adults aged 45 to 65 and found that women with higher levels of total and abdominal fat were more likely to have lower vitamin D levels, with abdominal fat most associated with vitamin D deficiency. The findings, presented at the annual meeting of the European Society of Endocrinology, also showed an association between higher levels of fat in the abdomen and liver with lower vitamin D levels in men.

Full Story:
Medical News Today
More Summaries:
vitamin D deficiency
5/22/2018

The FDA granted an investigational device exemption to Beta Bionics to allow the company to begin recruiting individuals for the first home-based studies evaluating the safety and efficacy of the insulin-only configuration for its bionic pancreas system. The study will use conventional insulin aspart and insulin lispro with Beta Bionics' iLet bionic pancreas system in children and adults with type 1 diabetes, and Novo Nordisk's fast-acting insulin aspart with the iLet among adult type 1 diabetes patients.

More Summaries:
Beta Bionics, Novo Nordisk, diabetes, FDA
5/22/2018

Japanese scientists used CRISPR-Cas9 gene-editing technology to disrupt two genes in HIV-1, halting replication of the dormant virus in T cells during in vitro tests, according to a study in the journal Scientific Reports. "We now need to investigate how we can selectively introduce a CRISPR-Cas9 system that targets HIV-1 genes into the infected cells of patients," co-author Masanori Kameoka of Kobe University said.

More Summaries:
Kobe University
5/22/2018

In a study of patients with newly diagnosed T-cell acute lymphoblastic leukemia, aged 1 to 30, those who received standard chemotherapy with the addition of nelarabine had rates of four-year disease-free survival of 84.1% and overall survival of 90.2%, according to a study to be presented at the American Society of Clinical Oncology meeting.